Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Finance
Multiple Sclerosis -- KOL Insight and Consensus Outlook Modules

Multiple Sclerosis -- KOL Insight and Consensus Outlook Modules - new market research report published


Print article Print article
© companiesandmarkets.com

companiesandmarkets.com
companiesandmarkets.com
2014-01-24 13:59:01 - Multiple Sclerosis -- KOL Insight and Consensus Outlook Modules - a new market research report on companiesandmarkets.com

The multiple sclerosis treatment landscape has undergone dramatic changes over the past year. Biogen´s Tecfidera has revolutionised multiple sclerosis treatment in the U.S., eroding significant market share from older therapies. However, patent concerns has stalled Tecfidera´s launch in Europe. Genzyme have taken advantage of this delay with Lemtrada´s (alemtuzumab) and Aubagio´s (teriflunomide) EU approval. The arrival of these drugs is expected to transform multiple sclerosis treatment and be a catalyst for unprecedented market growth.

Over the next five years, the global multiple sclerosis market is set to grow from $14.4 billion in 2012 to $18.3 billion in 2017. Primary drivers of this growth will be the entry of new pipeline therapies, satisfying the unmet needs of convenient administration and more efficacious

 

 

therapy, and continued uptake of existing therapies.

A Complete Ongoing Analysis of Current Trends, Future Forecasts and Landscape Modifiers

For instant access to an accurate, unbiased, qualitative review of the latest treatment trends along with a five-year quantitative diabetes market forecast look no further than Therapy Trends: Multiple Sclerosis. This comprehensive research is available in two comprehensive modules:

- The KOL Insight: Multiple Sclerosis module provides a complete review and is enhanced with exclusive in-depth interviews with leading KOLs from the US and Europe
- The Consensus Outlook: Multiple Sclerosis data analysis module provides annual historical and forecast product-level sales data from an average of leading equity analysts´ projections

Report Scope

KOL Insight
Therapy Trends KOL Insight: Multiple Sclerosis analyses the current and predicted key issues, current products and late-stage pipeline products. The report gives you qualitative, inside information from exclusive interviews with 12 key opinion leaders (KOLs) through the following:

- KOL Insight Report — an in-depth analytical report on diabetes treatment trends
- Full report updates — issued to you after each and every significant diabetes market event
- Event Bulletins — the latest KOL views in response to each event

Key Report Features and Benefits

- Critical insights on products and market developments from leading US and European clinicians

- Critical insights on products and market developments from leading US, European and Australian clinicians
- Assessment of current leading multiple sclerosis products
- Analysis of late-stage pipeline multiple sclerosis therapies
- Competitive evaluation of leading players
- Current thinking and trends in the treatment of multiple sclerosis
- Predicted KOL treatment trends and market leaders
- Ongoing clinical and market updates

Expert Opinion for Real World Insights

The data and analysis in the report is enriched through the specific insights and opinions of leading clinicians working in multiple sclerosis in the US, Europe and Australia. Their views on specific drugs and treatment pathways provide a unique front line perspective from those working in clinical setting. The results of these detailed and extensive interviews are incorporated though out the text so they can be read in the context of the issue or product being discussed.

KOL Panel

- David Hafler, Chief and Chair of Neurology at Yale-New Haven Hospital and Yale School of Medicine, New Haven, Connecticut, US
- Professor Douglas Jeffery, MD, PhD, Associate Professor of Neurology, the Department of Neurology, The Multiple Sclerosis and Movement Disorders Centre at Advance Neurology at Cornerstone Health Care Winston-Salem, North Carolina, US
- Professor Paul O´Connor, Professor, Division of Neurology, University of Toronto, Toronto, Canada
- Professor Lawrence Steinman, Professor of Neurology and Neurological Sciences, Pediatrics, and Genetics, Stanford University School of Medicine, California, US
- Professor and Medical Neurologist, MD, and expert in multiple sclerosis at the Ottawa Hospital Research Institute, Ottawa, Canada (requested anonymous)
- Professor and Medical Neurologist, MD, and expert in multiple sclerosis at the Mount Sinai School of Medicine, New York, US (requested anonymous)
- Dr Mike Bogglid, Staff Specialist Neurologist, Townsville Hospital, University of Queensland, Australia
- Dr Patrick Vermersch, Department of Neurology, University of Lille North of France, Hôpital Roger Salengro, Lille, France
- Dr Heinz Wiendl, Department of Neurology, Neuroimmunology and Neuro-Oncology, University of Muenster, Muenster, Germany
- Dr Martin Wilson. Consultant Neurologist, Walton Centre for Neurology and Neurosurgery NHS Trust, Liverpool, UK
- Professor and Medical Neurologist, MD, and expert in multiple sclerosis at Centre Neurologique et de Réadaptation Fonctionnelle, Fraiture-en-Condroz, Belgium (requested anonymous)
- Professor and Medical Neurologist, MD, and expert in multiple sclerosis at Heinrich-Heine University, Düsseldorf, Germany (requested anonymous)

Key Quotes from the Report

"I think alemtuzumab is an excellent drug. It´s very, very efficacious, and surprisingly well tolerated, considering its potency. They do need some blood monitoring each month but it´s actually pretty easy to give and to monitor and certainly very effective." Dr Martin Wilson (Europe)

"Using Lemtrada is different from the other options we have available. It is a real investment in the patient´s time. You enter into a contract over five years at least with monthly monitoring. That is something that a lot of patients cannot really foresee when they start such therapies. They need to have a certain insight into the disease and its nature. This is a difference between, let´s say, a drug that you rather easily start on and get off, like Tecfidera versus Lemtrada, that is something you start and you don´t get off ever." Dr Heinz Wiendl (EU)

"I think teriflunomide is moderately effective. It seems that there are no major severe risks. I would put it in the efficacy range of the current injectables, I don´t think it offers an advantage over the currently available first-line drugs, but of course, as a tablet it´s more convenient and would hold the promise of increasing adherence" European Key Opinion Leader

KOL Insights -- Key Topics

- Current multiple sclerosis marketplace
- Current treatment landscape
- Reimbursement of key multiple sclerosis brands
- Unmet needs
- Current therapies
- Symptomatic treatment
- Pipeline therapies
- Future developments in multiple sclerosis

Consensus Outlook
Use this detailed report and powerful interactive Excel spreadsheet to compare and contrast companies and products now and in the future. Therapy Trends Consensus Outlook: Multiple Sclerosis includes the following comprehensive resources:

- An in-depth 5-year forecast report based on analyst consensus, mapping the impact of future events to predicted product performance
- A detailed forecast data analysis spreadsheet model comparing critical market parameters including market size, product sales, market shares and competitive status over the period 2007 to 2017
- Timely event-driven market forecast report and data analysis updates over the next 12 months

Report features:

- Historical MS sales from 2007–2012
- Forecast MS sales from 2013-2017
- Key competitors and drug developers
- Predicted product positioning
- Current and late-stage pipeline drugs
- Future event mapping to forecast data points
- Comparative clinical trial results

Use Consensus Outlook to:

- Chart predicted market growth and product sales
- Map your own market parameters
- Tailor your strategic and investment focus
- Assess your current and future sales resources
- Set proactive launches and branding strategies

Analysts compared:

- Barclays Capital
- Credit Suisse
- Deutsche Bank
- Goldman & Sachs
- International Strategy & Investment
- Jefferies
- JP Morgan
- Merrill Lynch
- Morgan & Stanley
- Societe Generale
- Stifel Nicolaus
- UBS
- Wells Fargo

Content Highlights and Products Covered:

- Research Methodology
- Multiple Sclerosis Marketplace
- Key Multiple Sclerosis Developers
- Multiple Sclerosis Class Dynamics
- Tecfidera (dimethyl fumarate; Biogen) forecast
- Aubagio (teriflunomide; Sanofi) forecast
- Gilenya (fingolimod; Novartis Mitsubishi Tanabe) forecast
- Tysabri (natalizumab; Biogen) forecast
- Copaxone (glatiramer acetate; Teva) forecast
- Avonex (interferon beta-1a; Biogen) forecast
- Betaseron (interferon beta-1b; Bayer) forecast
- Rebif (interferon beta-1a; Merck Serono) forecast
- Extavia (interferon beta-1b; Novartis) forecast
- Lemtrada (alemtuzumab; Genzyme/Sanofi) forecast
- Laquinimod (Teva/Active Biotech) forecast
- Daclizumab HYP (Biogen/AbbVie) forecast
- Ocrelizumab (Biogen/Roche/Biogen) forecast

Reasons to Buy

Ongoing Benefits
Continually Updated in Response to Market Developments
The world of pharma is ever changing and executives must always be up-to-date with the latest developments that could affect their own products, position and research. That is why we guarantee to keep Therapy Trends updated offers real commercial advantage.

Consider the benefits:

- Content will be fully updated in response to market developments such as new product approvals or pivotal research results for 12 months from the date of purchase
- Such updates are incorporated throughout the KOL reports ensuring the change is reflected in every aspect of the report
- There is no limit and all relevant events will result in an update
- You´ll receive these updates directly, within days of each event´s occurrence
- All updates are included in the price

Whatever happens in the market you´ll always be able to assess the impact with Therapy Trends
Unrivalled Sources Ensure Complete Coverage
Our unique disease selection matrix pinpoints those disease sectors of the highest commercial potential, and draws information from multiple novel and expert sources, including:

- Exclusive views from leading global experts
- Comprehensive consensus research
- Live dispatches and critical industry data
- Online opinions from 535,000 vetted physicians
- Data from over 125 medical conferences each year
- Over 2,000 peer-reviewed medical journals
- Over 450 pharmaceutical news sources

Click for report details: www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..

Browse all Healthcare and Medical Market Research Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..

Browse all Healthcare and Medical Company Profile Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Compan ..

Browse all Latest Market Research Reports www.companiesandmarkets.com/Market/All/Market-Research?aCode=f3f ..

About Us
Companiesandmarkets.com is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles, Companiesandmarkets.com’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.


Author:
Mike King
e-mail
Web: www.companiesandmarkets.com
Phone: London: +44 (0) 203 086 8600

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com